Stock News•1 months ago
Amgen Drops 10% on a Trial It Didn't Even Run
Amgen shares fell 10% after a trial it did not run reported results, despite the company delivering a strong earnings report on Aug. 4.
MarketLens
What's Driving Amgen's Recent Volatility
4 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
What's Driving Intel's Recent Volatility
7 months ago
What's Driving Paysafe's Recent Volatility
7 months ago
What's Driving Intuit's Recent Volatility
6 months ago
Category
You may also like
Stock News•1 months ago
Amgen Touches 52-Week High: Buy, Sell or Hold the Stock?
Amgen (AMGN) touched a 52-week high, supported by strong growth drivers and a promising pipeline, though patent losses, pricing pressure, and valuation warrant caution.
Stock News•2 months ago
Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript
Amgen reported Q2 2026 results, with revenue and earnings changes driven by product performance and updated guidance. The earnings call provided insights into operational trends and future outlook.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Stock News•1 hour ago
Why the Market Dipped But Microsoft (MSFT) Gained Today
Stock News•1 hour ago
Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Stock News•1 hour ago
Tesla (TSLA) Declines More Than Market: Some Information for Investors
Stock News•1 hour ago